AGENDA DAY 1

 

 

Day 1 Oct 10th Immune Profiling

11:40

Chair’s opening remarks

Dr Nikolai Petrovsky
11:45

Why haven't Alzheimer's vaccines succeeded yet?

 
  • Abeta and tau still valid AD targets
  • Past AD vaccines were very poorly immunogenic, explaining lack of efficacy
  • Structured AD vaccine design ensures maximal immune recognition
  • Good adjuvants are essential for effective AD vaccines
Jeffrey D Abbey
12:15

Delivering precision immunotherapy - Reprogramming dendritic cells to target patient specific antigens


 
Dr Peter Timmerman
12:45

Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity

13:15

Networking Lunch & Poster Session

Trevor Clancy
14:45

A pan-HLA predictor of antigen processing and presentation to the cell surface improves the identification of clinically relevant neoantigens

Salim Mujais
15:15

Using DNA vaccine based technology to prevent potentially life threatening allergies

Dr Willem-Jan Krebber
15:45

Data supporting the value of check point inhibitors, AMPLIVANT SLP conjugates and neoantigens in combinational immunotherapy against HPV cancers

16:15

Networking Break

Angus Dalgleish
16:45

The rationale of combining biomarkers and checkpoint inhibitors with vaccines and oncolytics

 
  • Use of biomarkers in cancer vaccine and combinational studies
Dr Brian Champion
17:15

Oncolytic viruses as immunotherapy - Establishing the legitimacy of oncolytic viruses in cancer therapy

 
  • Combinational potential with other immunotherapies
17:45

Chair closing remarks of day one followed by Drinks Reception

last published: 06/Oct/17 08:25 GMT